A Phase II Trial of Pemetrexed Versus Erlotinib as Second-Line Therapy in Treating Patients With EGFR Wild-type Advanced Lung Adenocarcinoma
This trial will compare the efficacy of pemetrexed versus erlotinib in patients with EGFR
wild-type advanced lung adenocarcinoma.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Siyu Wang, Doctor
Sun Yat-sen University
China: Ethics Committee